Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Prognostic significance of mucin expression profiles in breast carcinoma with signet ring cells: a clinicopathological study.

Ohashi R, Hayama A, Yanagihara K, Yamashita K, Sakatani T, Takei H, Naito Z.

Diagn Pathol. 2016 Nov 15;11(1):131.

2.

Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study.

Menekse E, McKolanis J, Finn OJ, McAuliffe PF, Johnson R, Soran A.

Dis Markers. 2015;2015:179689. doi: 10.1155/2015/179689. Epub 2015 Nov 29.

3.

Prognostic Significance of Mucin Antigen MUC1 in Various Human Epithelial Cancers: A Meta-Analysis.

Xu F, Liu F, Zhao H, An G, Feng G.

Medicine (Baltimore). 2015 Dec;94(50):e2286. doi: 10.1097/MD.0000000000002286. Review.

4.

Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene.

Choong ML, Yong J, Wang Y, Lee MA.

Biores Open Access. 2014 Aug 1;3(4):176-82. doi: 10.1089/biores.2014.0011.

5.

Cell Models for the Investigation of the Role of the Mucin MUC1 Extracellular Domain in Metastasizing.

Syrkina MS, Rubtsov MA, Potashnikova DM, Kondratenko YD, Dokrunova AA, Veiko VP.

Acta Naturae. 2014 Apr;6(2):62-70.

6.

MicroRNA-dependent regulation of transcription in non-small cell lung cancer.

Molina-Pinelo S, Gutiérrez G, Pastor MD, Hergueta M, Moreno-Bueno G, García-Carbonero R, Nogal A, Suárez R, Salinas A, Pozo-Rodríguez F, Lopez-Rios F, Agulló-Ortuño MT, Ferrer I, Perpiñá A, Palacios J, Carnero A, Paz-Ares L.

PLoS One. 2014 Mar 13;9(3):e90524. doi: 10.1371/journal.pone.0090524. eCollection 2014.

7.

Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy.

Kovjazin R, Horn G, Smorodinsky NI, Shapira MY, Carmon L.

PLoS One. 2014 Jan 8;9(1):e85400. doi: 10.1371/journal.pone.0085400. eCollection 2014.

8.

Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature.

Demichelis SO, Isla-Larrain MT, Cermignani L, Alberdi CG, Segal-Eiras A, Croce MV.

Breast Cancer (Dove Med Press). 2011 Dec 20;3:161-73. doi: 10.2147/BCTT.S26833. eCollection 2011.

9.

Natural and Induced Humoral Responses to MUC1.

Von Mensdorff-Pouilly S, Moreno M, Verheijen RH.

Cancers (Basel). 2011 Jul 29;3(3):3073-103. doi: 10.3390/cancers3033073.

10.

MUC1 and metastatic cancer: expression, function and therapeutic targeting.

Horm TM, Schroeder JA.

Cell Adh Migr. 2013 Mar-Apr;7(2):187-98. doi: 10.4161/cam.23131. Epub 2013 Jan 9. Review.

11.

Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.

Ghosh SK, Uchida M, Yoo B, Ross AW, Gendler SJ, Gong J, Moore A, Medarova Z.

Int J Cancer. 2013 Apr 15;132(8):1860-7. doi: 10.1002/ijc.27872. Epub 2012 Oct 25.

12.

MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.

Kufe DW.

Oncogene. 2013 Feb 28;32(9):1073-81. doi: 10.1038/onc.2012.158. Epub 2012 May 14. Review.

13.

Core-glycosylated mucin-like repeats from MUC1 are an apical targeting signal.

Kinlough CL, Poland PA, Gendler SJ, Mattila PE, Mo D, Weisz OA, Hughey RP.

J Biol Chem. 2011 Nov 11;286(45):39072-81. doi: 10.1074/jbc.M111.289504. Epub 2011 Sep 20.

14.

Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK.

Biochim Biophys Acta. 2011 Apr;1815(2):224-40. doi: 10.1016/j.bbcan.2011.01.001. Epub 2011 Jan 26. Review.

15.

Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein.

Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, Bates P.

PLoS Pathog. 2010 Sep 9;6(9):e1001098. doi: 10.1371/journal.ppat.1001098.

16.

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.

Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedli Stark F, Courtenay Luck N.

Breast Cancer Res. 2009;11(5):R73. doi: 10.1186/bcr2409.

17.

Analysis of differential expression of glycosyltransferases in healing corneas by glycogene microarrays.

Saravanan C, Cao Z, Head SR, Panjwani N.

Glycobiology. 2010 Jan;20(1):13-23. doi: 10.1093/glycob/cwp133. Epub 2009 Sep 7.

18.

Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells.

Fanayan S, Shehata M, Agterof AP, McGuckin MA, Alonso MA, Byrne JA.

BMC Cell Biol. 2009 Jan 28;10:7. doi: 10.1186/1471-2121-10-7.

19.

Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein.

Francica JR, Matukonis MK, Bates P.

Virology. 2009 Jan 20;383(2):237-47. doi: 10.1016/j.virol.2008.10.029. Epub 2008 Nov 14.

20.

Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells.

Pavoni E, Monteriù G, Santapaola D, Petronzelli F, Anastasi AM, Pelliccia A, D'Alessio V, De Santis R, Minenkova O.

BMC Biotechnol. 2007 Oct 18;7:70.

Supplemental Content

Support Center